The Fool Looks Ahead

There's never a dull week on Wall Street. Let's go over some of the news that will shape the week to come.

Monday
The market kicks off with TrustCo (NASDAQ: TRST  ) reporting quarterly results on Monday. Many of the "too big to fail" institutions reported in recent days, but now it's time to check out some of the regional players. TrustCo has 138 offices through the Northeast and Florida, watching over $4.3 billion in assets.

Tuesday
AK Steel (NYSE: AKS  ) hopes to "steel" the show on Tuesday. The producer of flat-rolled carbon, stainless, and electrical steels is expected to post another quarterly deficit. AK Steel provided guidance last month that calls for a sequential dip in production. It was expecting to ship between 1.275 million and 1.3 million tons of steel during the first three months of the year, and that's less than the more than 1.4 million tons it shipped during the fourth quarter of last year.

The good news is that analysts are expecting a substantially narrower loss out of AK Steel than it rolled out during the prior year's freshman quarter.

Wednesday
New York Community Bancorp (NYSE: NYCB  ) is another regional banker reporting this week. One of its more notable features is its chunky dividend. A hefty yield of 7.3% will turn heads in just about any industry, but is it sustainable? Analysts see slight dips in revenue and earnings per share in Wednesday's report.

Thursday
Tellabs
(NASDAQ: TLAB  ) checks in on Thursday. The provider of mobile backhaul, packet optical, and services solutions to communications services lost its CEO to colon cancer last year. It has also lost its mojo. Wall Street sees Tellabs merely breaking even in 2013 on a 14% decline in revenue.

Friday
The market is typically quiet on Friday, but that's certainly not the case during earnings season. AbbVie's (NYSE: ABBV  ) report will be the branded medicine marketer's first public quarter as a standalone company since being spun off by Abbot Labs in January. Abbot Labs itself posted encouraging results a few days ago. Now it's time to see how AbbVie holds up.

Abbott Labs has changed forever after losing its branded pharmaceutical business to a spinoff. If you're a current investor, or might be buying shares soon, make sure you truly understand the stock by reading The Motley Fool's brand new premium report on Abbott Labs. The report outlines all of the must-know opportunities and risks, along with a full year of analyst updates to keep you up to speed. Best of all, you can claim this report today by clicking here now.


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2374834, ~/Articles/ArticleHandler.aspx, 9/2/2014 3:01:41 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement